Appointments at Phage Pharmaceuticals, the USP and Nycomed – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Board of directors Chairman

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Phage Pharmaceuticals, the USP and Nycomed.

David Jackson ​has been named as vice president (VP), operations planning at Phage Pharmaceuticals​. In this capacity Jackson will oversee the firm’s current good manufacturing practice (cGMP) production facility in San Diego, California, US.

Jackson joins from VaxInnate and has also held manufacturing positions at Lonza Biologics, BioReliance and EntreMed.

The US Pharmacopeia ​(USP​) has nominated two Hovione ​scientists to its expert committees for the period 2010 to 2015. Jason Suggett ​has been named to the General Chapters – Dosage Forms Expert Committee and Nuno Matos​ to the Chemical Analysis Expert Committee.

Steve Andrzejewski​ has been appointed as CEO of Nycomed US​. Andrzejweski will have responsibility for manufacturing sites in Melville and Hicksville, New York, US. He has previously worked at King Pharmaceuticals, Schering-Plough and Endo Pharmaceuticals.

Amgen ​has elected Ronald Sugar ​to its board of directors. Sugar will also serve as a member of the compensation and management development committee and the nominating committee.

Pat Long​, vice chairman and co-founder of logistics service provider Longistics​, has been appointed to the North Carolina Logistics Task Force​. The task force is charged with evaluating current transportation options in North Carolina.

3-V Biosciences ​has elected James Young ​to its board of directors. Young worked at MedImmune for 19 years, from its founding until 2008 after it was sold to AstraZeneca.

John Bailye ​has been named as CEO of EKR Therapeutics​. Bailye joined the company in 2009 as executive chairman and has also worked at Dendrite. EKR also appointed Bill McKee ​as chief operating officer. McKee joined last month having worked at Barr Pharmaceuticals for 15 years.

Related topics Markets & Regulations

Related news

Show more